Have any questions? 706-721-6582 or cts@augusta.edu
- (Verona Pharma) A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Ensifentrine in Subjects with Non-Cystic Fibrosis Bronchiectasis
Clinical Trial
(Verona Pharma) A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Ensifentrine in Subjects with Non-Cystic Fibrosis Bronchiectasis
This study investigates the efficacy and safety of ensifentrine in patients with noon-cystic fibrosis bronchiectasis, as compared to a placebo. Participants will be in the study for at least 7 months with 6 clinic visits, and may be able to participate for up to three years.
Eligibility Criteria
- Inclusion Criteria: *Male or female 18 to 85 years of age *Current diagnosis of of non-cystic fibrosis bronchiectasis confirmed by chest CT Exclusion Criteria: *Diagnosis of COPD or asthma *Current smoker *Worsening of bronchiectasis or another infection requiring antibiotics within 4 weeks of enrollment
RESEARCH. INNOVATION. DISCOVERY.